Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 07 05 2018
accepted: 08 02 2019
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 26 11 2019
Statut: epublish

Résumé

As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans ε-viniferin induced the disaggregation of Aβ42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans ε-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.

Identifiants

pubmed: 30785960
doi: 10.1371/journal.pone.0212663
pii: PONE-D-18-13651
pmc: PMC6382128
doi:

Substances chimiques

Benzofurans 0
Stilbenes 0
epsilon-viniferin 62218-08-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0212663

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Neurosci Lett. 2002 Aug 16;328(3):269-72
pubmed: 12147323
Fundam Clin Pharmacol. 2003 Aug;17(4):419-28
pubmed: 12914543
Neurobiol Aging. 2015 Apr;36(4):1639-1652
pubmed: 25680265
Curr Alzheimer Res. 2012 Mar;9(3):344-60
pubmed: 22272616
Brain Res. 2007 Jan 12;1128(1):40-9
pubmed: 17125750
J Neuroinflammation. 2014 Aug 27;11:139
pubmed: 25158693
Bioorg Med Chem. 2011 May 15;19(10):3152-5
pubmed: 21524590
Biochim Biophys Acta. 2013 Nov;1830(11):5068-74
pubmed: 23830862
Trends Pharmacol Sci. 2017 Nov;38(11):956-966
pubmed: 28867259
Neurology. 2015 Oct 20;85(16):1383-91
pubmed: 26362286
Neuropharmacology. 2014 Jan;76 Pt A:27-50
pubmed: 23891641
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3441-3
pubmed: 20452207
Nature. 2000 Dec 21-28;408(6815):979-82
pubmed: 11140685
J Biol Chem. 2010 Jul 30;285(31):24228-37
pubmed: 20511235
Lancet Neurol. 2010 Jul;9(7):702-16
pubmed: 20610346
Neurosci Lett. 2014 Apr 17;565:30-8
pubmed: 24406153
PLoS One. 2013;8(3):e59888
pubmed: 23555824
Mol Cell Neurosci. 2018 Apr;88:1-6
pubmed: 29223600
J Nat Prod. 2014 Jul 25;77(7):1658-62
pubmed: 25014026
Neurobiol Dis. 2006 Dec;24(3):516-24
pubmed: 17029828
J Neurochem. 2012 Feb;120(3):461-72
pubmed: 22118570
Neurobiol Aging. 2004 Aug;25(7):885-92
pubmed: 15212842
Neurobiol Dis. 2005 Apr;18(3):602-17
pubmed: 15755686
Curr Alzheimer Res. 2009 Dec;6(6):531-40
pubmed: 19747158
Biochim Biophys Acta. 2014 Sep;1842(9):1556-66
pubmed: 24887203
Behav Brain Res. 2014 May 1;264:173-80
pubmed: 24512768

Auteurs

Martial Caillaud (M)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.

Jérôme Guillard (J)

University of Poitiers, UMR CNRS 7285 Institute of Chemistry of Poitiers: Materials and Natural Resources, POITIERS, France.

Damien Richard (D)

Department of Pharmacology and biological Toxicology, UMR INSERM 1107, Clermont-Ferrand, France.

Serge Milin (S)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.
Poitiers University Hospital, Department of Pathology, Poitiers, France.

Damien Chassaing (D)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.

Marc Paccalin (M)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.
Poitiers University Hospital, Geriatrics Department, Poitiers, France.
Poitiers University Hospital, CMRR, Poitiers, France.

Guylène Page (G)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.

Agnès Rioux Bilan (A)

University of Poitiers, EA3808 Neurovascular Unit and Cognitive Disorders, Pôle Biologie Santé, POITIERS, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH